Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03534804
Title Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Acronym PemCab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Winship Cancer Institute, Emory University Atlanta Georgia 30322 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field